Published on 28/12/2025

Navigating Site Selection Challenges in Emerging Markets for Clinical Trials

Emerging markets—such as parts of Asia, Africa, Latin America, and Eastern Europe—are becoming increasingly attractive for clinical trial conduct. These regions offer large treatment-naïve populations, reduced costs, and diverse disease prevalence. However, site selection in emerging markets comes with its own set of logistical, regulatory, and infrastructure challenges. This tutorial explores the hurdles faced during site selection and offers practical strategies for successful trial start-up in these regions.

Table of Contents

Why Target Emerging Markets?

Pharmaceutical sponsors and CROs are drawn to emerging markets due to:

High patient recruitment potential and fast enrollment
Lower operational costs compared to Western countries
Unmet medical needs and disease-specific opportunities
Expansion of regulatory frameworks and clinical infrastructure

However, balancing opportunity with operational risk is crucial for long-term success.

Common Site Selection Challenges in Emerging Markets:

1. Inadequate Research Infrastructure

Lack of reliable power supply and internet connectivity
Limited access to advanced diagnostics or storage facilities for IP
Scarcity of validated stability studies or temperature-controlled storage for sensitive biologics

This can compromise protocol compliance and data quality.

2. Regulatory and Ethics Approval Delays

Lengthy timelines for IRB/IEC and regulatory approval processes
Unpredictable timelines from Ministries of Health or national regulatory authorities
Insufficient alignment with ICH-GCP or CDSCO expectations

These delays can significantly impact

trial start-up timelines and budget forecasts.

3. Limited Investigator Experience

Sites may lack prior experience with interventional trials
Training gaps in GCP and EDC systems
Dependence on busy government hospitals with overburdened staff

Such issues require early engagement and hands-on mentoring from CRAs or regional CROs.

4. Language and Cultural Barriers

Protocol and informed consent forms require translation into multiple local languages
Low literacy levels may complicate informed consent procedures
Miscommunication between sponsors, monitors, and site teams

Localization of training materials and interpreters may be needed for patient-facing documents.

5. Unpredictable Logistics and Import Delays

Delayed import licenses for investigational products and lab kits
Custom clearance issues and local regulatory bottlenecks
Variable reliability of local couriers for biological sample shipments

Logistics partners with regional experience are critical for seamless operations.

6. Weak Documentation and SOP Adherence

Sites may lack formal SOPs or follow inconsistent practices
Limited documentation of delegation, AE/SAE reporting, and IP accountability
Poor archiving practices and limited audit readiness

Providing templates and training from Pharma SOPs can standardize operations and improve inspection outcomes.

Key Strategies to Overcome Challenges:

1. Robust Feasibility Assessments

Use detailed feasibility questionnaires with site capability scoring
Conduct virtual pre-selection visits with real-time video assessments
Evaluate past trial performance through CTMS and registry data

2. Partner with Regional CROs

Leverage CROs with strong regulatory networks and linguistic capabilities
Use local field monitors who understand regional norms and site dynamics
Benefit from existing site relationships and established logistics chains

3. Investigator and Staff Training Programs

Organize on-site and remote GCP training tailored to the site’s level
Train staff on EDC, eTMF, and safety reporting platforms
Set up mentorship programs where experienced investigators support novice teams

4. Regulatory Planning

Build in buffer timelines for document submission and MoH review
Work with local regulatory experts to navigate country-specific requirements
Pre-engage with IRBs to address template gaps and documentation expectations

5. Use of Hybrid and Decentralized Trial Models

Incorporate remote visits and e-consent tools where feasible
Outsource sample analysis to central labs with pickup networks
Use mobile monitoring and telemedicine to reach rural populations

Best Practices for Site Selection Success:

Use a site scorecard that includes infrastructure, staff experience, and compliance history
Pre-screen for access to target patient populations and competing studies
Confirm availability of trial-specific equipment and calibration certification
Clarify patient reimbursement mechanisms early
Ensure site access to power backups, secure storage, and internet connectivity

Conclusion:

Emerging markets offer great potential for expanding clinical research, but success depends on a deep understanding of local challenges. Through proactive feasibility assessments, regulatory planning, localized training, and robust partner selection, sponsors can transform obstacles into opportunities. With the right strategy, site selection in these regions can deliver both speed and quality—two pillars critical to the success of global clinical trials.